

Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type I with excessive daytime sleepiness [Corrigendum]

Omori Y, Kanbayashi T, Imanishi A, et al. *Neuropsychiatr Dis Treat*. 2018;14:451–457.

On page 451, the Result section in the abstract, 2nd sentence reads “There were significant differences in the ESS

scores and MSL between decreased and normal CSF orexin groups in DM1 patients” it should have been “Differences of the ESS scores and MSL between decreased and normal CSF orexin groups were insignificant among DM1 patients”.

Publish your work in this journal

Neuropsychiatric Disease and Treatment is an international, peer-reviewed journal of clinical therapeutics and pharmacology focusing on concise rapid reporting of clinical or pre-clinical studies on a range of neuropsychiatric and neurological disorders. This journal is indexed on PubMed Central, the ‘PsycINFO’ database and CAS,

and is the official journal of The International Neuropsychiatric Association (INA). The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <http://www.dovepress.com/neuropsychiatric-disease-and-treatment-journal>